Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

VJOncology

1 year
195 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results of the Phase III RIBECCA trial (NCT03096847) investigating the efficacy and safety of ribociclib with letrozole for HR+ metastatic or advanced breast cancer. Dr Fasching then compares their results with the previous MONALEESA-2 (NCT01958021) and MONALEESA-3 (NCT02422615) studies, which also focused on the use of ribociclib for breast cancer. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Up Next Autoplay
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
2 Views
Mount Sinai Health System 1 week
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
1 Views
Mount Sinai Health System 1 week
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
Category: Breast Cancer
31 Views
ash 3 weeks
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Category: Breast Cancer
17 Views
Cancer-News 3 weeks
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Category: Breast Cancer
6 Views
ash 3 weeks
Prognostic Marker in Operable Breast Cancer #SABCS19
Prognostic Marker in Operable Breast Cancer #SABCS19
Category: Breast Cancer
22 Views
admin 3 weeks
The FLEX Real World Data #SABCS19 @BaptistHealthSA
The FLEX Real World Data #SABCS19 @BaptistHealthSA
Category: Breast Cancer
26 Views
admin 3 weeks
Agendia Presents New Data at #SABCS19 in Breast Cancer
Agendia Presents New Data at #SABCS19 in Breast Cancer
Category: Breast Cancer
7 Views
admin 3 weeks
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
Category: Breast Cancer
12 Views
Cancer-News 1 month
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
18 Views
cancernewsupdate 1 month